Helicobacter pylori Eradication: Why Recurrence Risk Should Not Dictate Treatment Decisions

幽门螺杆菌根除:为何复发风险不应决定治疗方案

阅读:2

Abstract

Helicobacter pylori infection is unequivocally associated with the development and progression of various digestive diseases. Clinical guidelines recommend eradication therapy for all eligible patients without contraindications. However, reports of high recurrence rates in earlier studies have raised concerns among clinicians and patients regarding the necessity of treatment, which has, to some extent, hindered the timely implementation of eradication strategies. This article provides a systematic review of the issue of H. pylori recurrence. A comprehensive analysis of literature retrieved from major databases such as PubMed, Web of Science, and Google Scholar, using keywords including "Helicobacter pylori", "recurrence", and "reinfection", indicates that the annual recurrence rate is significantly lower than previously thought, with modern epidemiological estimates ranging from 1.5% to 5.0%. The review further elucidates the underlying mechanisms of recurrence, identifies key modifiable risk factors, and highlights that optimizing eradication regimens and preventing intrafamilial transmission are central strategies for controlling recurrence. The conclusion emphasizes that concerns about recurrence should not preclude eradication therapy and offers a theoretical basis and practical directions for developing targeted prevention strategies in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。